Label-Free Myoglobin Biosensor Based on Pure and Copper-Doped Titanium Dioxide Nanomaterials

Area of Science:

• Nanomaterials Science
• Biosensor Technology
• Biomedical Diagnostics

Background:

• Acute myocardial infarction (AMI) diagnosis relies on detecting cardiac biomarkers like myoglobin (Mb).
• Current diagnostic methods can be time-consuming or require complex procedures.
• Development of rapid, sensitive, and label-free biosensors is crucial for early AMI detection.

Purpose of the Study:

• To develop and characterize enzyme-less, label-free myoglobin biosensors.
• To utilize pure and copper-doped titanium dioxide (Cu-TiO2) nanostructures as the sensing platform.
• To evaluate the performance of the fabricated biosensor for acute myocardial infarction detection.

Main Methods:

• Copper-doped titanium dioxide (Cu-TiO2) nanomaterials were synthesized using a sol-gel method.
• Characterization of nanomaterials included techniques to assess morphology, composition, structure, optical, and electrochemical properties.
• Enzyme-less, label-free myoglobin biosensors were fabricated by immobilizing Cu-TiO2 nanomaterials onto a gold screen-printed electrode (Au-SPE).

Main Results:

• Synthesized Cu-TiO2 nanomaterials exhibited good crystallinity and high purity.
• The fabricated Cu-TiO2 nanomaterial-based myoglobin biosensor demonstrated high sensitivity (61.51 µAcm-2/nM).
• The biosensor achieved a low detection limit of 14 pM with a rapid response time of less than 10 ms and showed minimal interference from human serum albumin and cytochrome c.

Conclusions:

• Copper-doped titanium dioxide (Cu-TiO2) nanostructures are effective materials for developing highly sensitive and rapid enzyme-less, label-free myoglobin biosensors.
• The developed biosensor shows significant potential for the early and accurate detection of acute myocardial infarction.
• The facile synthesis and high performance make this biosensor a promising tool for point-of-care diagnostics.